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IN VITRO and in vivo data have demonstrated that
there are detectable differences between inhaled
corticosteroids commonly used to treat asthma.
However, controversy still remains as to whether
these differences translate into clinical benefits.
This 12-week, international, randomized, double-
blind, parallel-group study was undertaken to
compare the efficacy and safety of fluticasone
propionate (FP) 800 >g daily, administered as a
powder via the Diskhalerq, and budesonide
(BUD) 1 600 g daily, administered using the Tur-
buhaler, in adult patients with moderate-to-
severe asthma. A total of 518 patients participated
in the study, 256 of whom received FP and 262
BUD. Assessment of mean morning peak expira-
tory flow (PEF) over the 12-week treatment period
revealed a statistically significant difference in
efficacy between FP 800 g daily and BUD 1 600 btg
daily in favour of FP (p 0.003), with an overall
improvement of 20.9 l/min with FP compared
with 12.4 l/min on BUD. Statistically significant
differences in favour of FP were seen over the 12
weeks for mean evening PEF (p 0.04), diurnal
PEF variation (p 0.03) and percentage predicted
PEF (p =0.003), as well as forced expiratory
volume (p 0.008), forced vital capacity (p
0.02) and PEF (p =0.005) measured at clinic
visits. The median percentage of symptom-free
nights increased over the 12-week study period in
both treatment groups, with similar changes seen
for the median percentage of days with symptom
score < 2, rescue medication use and exacerba-
tions of asthma. The incidence of adverse events
was found to be comparable in the two treatment
groups. The geometric mean ratios of serum
cortisol levels were found to be 1.03 for FP,
indicating no mean hypothalamic-pituitary-adre-
nal axis suppression from baseline, and 0.93 for
BUD (p 0.0002 compared with FP). In summary,
FP 800 g daily showed a greater efficacy/safety
ratio in the treatment of moderate-to-severe asth-
ma than BUD 1 600 bg daily.
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Introduction
The objectives of anti-asthma therapy are to
abolish symptoms, prevent exacerbations and
maintain normal lung function. A number of
therapeutic approaches are available for the
clinical management of this condition, including
bronchodilators and anti-inflammatory agents.
In general, a stepwise approach is recom-
mended. Minimum therapy to maintain effective
control should be used, with the level of ther-
apy increased with increasing asthma severity.
Inhaled anti-inflammatory drugs are now re-
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commended in international guidelines for the
treatment of even mild asthma, with cortico-
steroids being the therapy of choice.1’2 The
introduction of inhaled corticosteroids in the
1970s represented a significant advance in the
treatment of asthma, combining high topical
potency with low systemic activity compared
with oral administration. Although adequate
asthma control can be achieved with low doses
of inhaled corticosteroids (200-800 tg daily),
some patients may continue to have reduced
lung function and experience asthma symptoms
necessitating the administration of higher doses
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(1600-2000 pg daily). Preliminary data sug-
gest that high doses of inhaled corticosteroids
may have a role in the treatment of asthma
exacerbations.3 However, while older cortico-
steroids such as budesomide (BUD) and beclo-
methasone dipropionate (BDP) generally do not
produce clinically significant systemic adverse
effects at low doses, they may suppress the
hypothalamic-pituitary:adrenal (HPA) axis func-
tion at higher doses.
4-6 There is therefore a
clear need for new inhaled corticosteroids with
a high topical potency combined with a re-
duced potential for systemic effects.
Fluticasone propionate (FP) is a topical corti-
costeroid which has been shown in vitro (Table
1) to be more potent than either BDP or BUD,
with the advantage of a lower oral bioavail-
ability7
-11 This is significant, as up to 80% of
any inhaled dose may be swallowed and possi-
bly absorbed into the circulation, increasing the
potential for systemic adverse effects.4 How-
ever, there has been some criticism as to the
relevance of in vitro data being used to predict
improved clinical benefit when treating patients
with asthma. Clinical experience to date has
shown that at equal doses, FP is more effective
than either BDP or BUD for the treatment of
moderate-to-severe asthma in adults12a3 and to
have an approximate 2:1 potency ratio com-
14 pared with other inhaled corticosteroids. 17
This double-blind study was designed to show
equivalent efficacy and compare the tolerability
of FP at a relatively high dose of 800 lag daily
administered as a powder in adults with moder-
ate-to-severe asthma, versus BUD 1 600 bg daily,
an established treatment in this indication.
Patients and Methods
Study design
This was an international, double-blind, double-
dummy, parallel-group study, with a treatment
duration of 12 weeks preceded by a 2-week
run-in period. Study visits took place at the start
of the run-in and treatment periods, and after 4,
8 and 12 weeks of therapy. Patients were
randomized to receive either FP 800 btg daily,
administered as a powder via the Diskhaler(R), or
BUD 1 600 tg daily, administered by the Turbu-
haler(R) Patients received their usual inhaled
steroid during the run-in period and switched
to the study drug at the start of the treatment
period.
Salbutamol was used throughout the study as
rescue medication. All concomitant asthma
medication (except oral corticosteroids and
short-acting 2 agonists other than salbutamol)
were permitted, provided they had been taken
at a constant dosage for 4 weeks prior to visit 1
and during run-in. Any changes in concomitant
therapy were documented.
The study was conducted to Good Clinical
Practice in accordance with the Declaration of
Helsinki (Hong Kong Amendment 1989), and
approved by local ethics committees. Patients
gave written or witnessed oral consent to
participate.
Patients
Patients were aged 18 to 75 years, with a
documented clinical history of reversible air-
ways obstruction treated with inhaled steroids
at a constant dosage for 4 weeks prior to study
entry (BDP or BUD at 800-1 600 bg/day or FP
at 400-800 bg/day). All patients were required
to have: (i) a forced expiratory volume in 1 s
(FEV1) of between 45% and 90% of the pre-
dicted value; (ii) a clear response to bronchodi-
lator therapy, defined as a mean morning peak
expiratory flow (PEF) over the last 7 days of the
run-in period of < 90% of the response ob-
tained following administration of salbutamol
400 lag or 800 btg at the start of the treatment
period; (iii) required two or more doses of a
bronchodilator, or to have had asthma symp-
toms (total score of > 2) on at least four of the
last 7 days of the run-in period.
Patients were excluded from the study if their
reversible airways obstruction was unstable; if
they had received oral corticosteroids; had a
Table 1. In vitro potency measures
Compound CD4+ T-cells:
cytokine secretion
(IC5o [nM] for IL5)9
Histamine release Eosinophil survival
IC50 (M)
11 (IC50[nM])
1
Beclomethasone dipropionate (BDP)
Triamcinolone acetonide
Budesonide (BUD)
Mometasone furoate
Fluticasone propionate (FP)
7.7 + 1.9
9.84-5.1
1.7 4- 0.7
0.34-0.1
0.24-0.1
1.0 x 10-9 138.7
2.0 x 10-8 23.8
5.9 x 10-1 8.5
3.0 x 10-1 NA
3.0 x 10-1 1.7
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respiratory tract infection or been admitted to withheld use of a short-acting bronchodilator
hospital for respiratory disease during the 4 for 4 h, and a long-acting bronchodilator or
weeks prior to study entry; or if they had theophylline for 12 h before attending the
required 16 or more doses of rescue salbutamol clinic. All adverse events were recorded, and
during the last 6 days of the run-in period, serum cortisol measurements were taken at
Patients with concomitant disease which might baseline and at the end of the study.
have interfered with assessment of study medi-
cation, hypersensitivity to inhaled cortico-
steroids, evidence of alcohol or drug abuse, and
pregnant or lactating women were also ex-
cluded from participation.
Efficacy assessments
Statistical analysis
For calculation of sample size, treatment
groups were considered equivalent if the 95%
confidence interval (CI) for the difference be-
tween treatments was < 15 1/min. Assuming a
standard deviation of 30-45 1/min, as seen in
The primary efficacy variable was morning previous studies, 260 evaluable patients per
PEE measured every day at weeks 1-12, with treatment group were required to ensure a
secondary variables of evening PEF, day- and power of at least 80%. It was anticipated that a
night-time symptom severity, symptomatic maximum number of 700 patients, recruited
bronchodilator use, clinical lung function mea- from approximately 50-60 centres, would be
surements (PEE FEV1 and forced vital capacity required to achieve this figure.
(FVC)) and exacerbation rate. Patients measured Data from the daily diary cards completed
their own PEF in the morning and evening, during the run-in period were used to establish
using a mini-Wright peak flow meter. PEF was baseline values. For the assessment period, data
measured in the morning before taking any were analysed for weeks 1-4, 5-8, 9-12 and
medication, and in the evening at least 4 h after 1-12. All efficacy data were analysed on an
bronchodilator use (preferably at least 12 h after intent-to-treat basis. To be included in the analy-
taking a long-acting or oral 2 agonist, or sis of a variable, patients were required to have
theophylline). Three measurements were taken, provided data from at least 1 day of the last
and the highest one recorded in a daily diary week of the run-in period and at least 1 day of
record card. the assessment period.
Symptom severity and bronchodilator use Diary card data from the treatment period
were recorded by the patients each day on a were used to calculate mean morning and
diary card. Day-time symptoms were rated on a evening PEE the diurnal variation in PEF (de-
scale of 0 to 5 as follows: 0 no symptoms; fined as the mean difference between the
1 symptoms for one short period; 2 symp- previous evening and next morning values)and
toms for two or more short periods; 3--symp- percentage predicted PEF for both treatments
toms for most of the day which did not affect over each assessment period. An analysis of
daily activities; 4 symptoms for most of the covariance was performed on these variables
day which did affect daily activities; 5 symp- using baseline values as a covariate.
toms so severe the patient could not work or In addition, the following variables were
perform normal daily activities. Night-time analysed by treatment and assessment period:
symptoms were rated on a scale of 0 to 4: percentage of days with a symptom score < 2;
O=no symptoms; 1 =symptoms causing the percentage of symptom-free nights; median
patient to wake once or early; 2 symptoms night-time symptom score; median day-time
causing the patient to wake twice or more symptom score; percentage of days and nights
(including early waking); 3 symptoms causing when additional bronchodilator medication was
the patient to be awake most of the night; not required; median day-and night-time rescue
4 symptoms so severe the patient did not medication requirement. These variables were
sleep at all. Exacerbation of asthma was defined analysed by the Wilcoxon rank-sum test. An
as requiring salbutamol more than eight times analysis of covariance was performed on the
per day on more than 3 days during any 6-day measurements of PEE FEV1 and FVC taken in
period, or a PEF value of < 85% of the baseline the clinic, using baseline values as a covariate.
morning value on 3 days during any 6-day All patients randomized to treatment were
period, included in the safety analysis. Differences in
Lung function measurements were performed .the number of exacerbations of asthma, with-
at the clinic at each of the five study visits, and drawals and adverse events between treatment
the highest of three PEE FEV1 and FC values groups were compared using the chi-squared
were recorded. Patients,were required to have test. Serum cortisol data were log transformed
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prior to analysis of covariance, using baseline
values as a covariate. All statistical tests per-
formed were two-sided, with p-values of < 0.05
considered significant. No adjustment to the p-
values were performed to take into account
multiple significance testing.
Results
Demography
Of the 518 patients randomized to treatment,
256 received FP and 262 BUD. Patient charac-
teristics are summarized in Table 2. Overall,
there was a slightly higher proportion of males
compared to females entering the study (53.9%
vs 46.1%). This difference was more marked in
the FP group (57.4% vs 42.6%) compared with
the BUD group, where the proportions were
equal (50.4% vs 49.6%). Apart from this finding,
the two treatment groups were found to be
well matched for all key demographic variables
at baseline.
A total of 49 patients withdrew from the
study; 25 from the FP group and 24 from the
BUD group. Reasons for withdrawal included
adverse events (ten on FP vs 13 on BUD), lack
of efficacy (two FP, one BUD), non-compliance
(three FP, two BUD), failure to return (four FP,
three BUD), not fulfilling entry criteria (four FP,
three BUD) and other reasons (two FP, two
BUD), with no significant differences between
treatment groups.
Table 2. Patient characteristics at baseline
Demographic variable ’FP BUD
800 Fg 600 Fg
Patients n 256 262
Sex
Male n (%) 147 (57.4) 132 (50.4)
Female n (%) 109 (42.6) 130 (49.6)
Age (mean [SD] years) 47.6 (14.8) 48.3 (14.0)
Caucasian n (%) 227 (88.7) 238 (90.8)
Smokers n (%) 43 (16.8) 54 (20.6)
Duration of RAO [mean (SD) 17.4 (14.6) 17.7 (12.8)
years]
No. exacerbations requiring 1.1 (1.5) 1.1 (2.3)
change of medication in last
12 months (mean [SD])
Patients hospitalized at least 27 (10.5) 29 (11.1)
once in last 12 months due
to exacerbation n (%)
Inhaled corticosteroid
treatment (#g/day) n (%)
BDP 400-< 200 62 (24.2) 61 (23.3)
BDP 200-2000 12 (4.7) 27 (10.3)
BUD 400-< 200 95 (37.1) 93 (35.5)
BUD 200-2 400 57 (22.3) 48 (18.0)
FP 400-500 24 (9.4) 26 (9.9)
FP 501-1 000 6 (2.3) 7 (2.3)
BDP beclomethasone dipropionate; BUD budesonide; FP fluti-
casone propionate; RAO reversible airways obstruction.
Efficacy
Morning and evening PEF improved over
baseline values in both treatment groups during
the course of the trial. For morning PEE greater
improvements were seen on FP than on BUD
(Fig. 1), resulting in statistically significant
differences favouring FP at each assessment
interval (p=O.O007, weeks 1-4 and 5-8;
p 0.002 weeks 9-12) and over the whole 12-
week treatment period (p= 0.003, Table 3).
The overall improvement in mean morning PEF
(baseline vs weeks 1-12)was 20.9 1/min (95%
CI: 16.2-25.5) with FP compared with 12.4 l/min
(95% CI: 8.1-16.7) on BUD. Morning PEF im-
proved by > 10% over the whole treatment
period in 27% of patients on FP compared with
18% on BUD.
Similar results were seen for evening PEF (Fig.
2, Table 3), with 20% of patients taking FP
improving by > 10% over the whole treatment
period compared with 15% on BUD.
Analysis of the diurnal variation in PEF and
percentage predicted PEE as well as clinic
assessments of lung function (PEE FEV1 and
FVC) also showed improvement in both treat-
ment groups, with intergroup differences for all
parameters evaluated attaining statistical signifi-
cance in favour of FP over the 12-week treat-
ment period (Table 3).
Patient diary card data revealed an improve-
ment in symptoms experienced by the patients-
over the course of the trial, with comparable
stability in median day- and night-time symptom
scores in both treatment groups. At baseline,
patients in both treatment groups had a symp-
tom score < 2 on only approximately 30% of
days. Between weeks 9 and 12, however, this
had increased to 95% with FP and 89% with
BUD (Table 4). Similarly, the percentage of
symptom-free nights improved from 28% at
baseline to 80% between weeks 9 and 12 for FP,
and 33% at baseline to 85% between weeks 9
and 12 for BUD (Table 4). There were no
statistically significant differences between
groups after controlling for centre. For all
measures of symptom severity, the largest im-
provement occurred during the first 4 weeks of
treatment in both treatment groups.
The improvement in asthma symptoms of
patients receiving therapy was also reflected in
a decrease in patients’ additional day- and night-
time bronchodilator use. For the percentage of
days with no additional bronchodilator use,
there was a statistically significant difference in
favour of FP over the period 9-12 weeks (Table
5). For the percentage of nights with no
additional bronchodilator use, similar improve-
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FIG. 1. Morning peak expiratory flow recorded from patient diary record cards.
Table 3. Changes in lung function on therapy
FP BUD p value
800 #g 600 #g
Mean (SD) morning PEF (I/min)
Baseline 372.8 (102.8) 361.4 (105.5) NS
1-12 weeks 393.9 (105.3) 372.6 (107.6) 0.003
Mean (SD) evening PEF (I/min)
Baseline 390.3 (103.6) 379.6 (103.3) NS
1-12 weeks 404.1 (103.9) 386.4 (106.1) 0.04
Mean (SD) diurnal variation (I/min)
Baseline 17.4 (31.9) 17.9 (31.0) NS
12 weeks 10.1 (23.5) 13.7 (25.1) 0.03
Mean (SD) percentage predicted PEF (I/min)
Baseline 79.5% (17.9) 78.2% (17.6) NS
1-12 weeks 84.1% (19.3) 80.7% (18.0) 0.003
Mean (SD) clinic PEF (I/min)
Baseline 401.3 (99.7) 385.0 (109.5) NS
Week 12 426.1 (110.8) 405.9 (109.0) 0.005
Mean (SD) clinic FEVl (I)
Baseline 2.26 (0.69) 2.21 (0.73) NS
Week 12 2.38 (0.77) 2.27 (0.77) 0.008
Mean (SD) clinic FVC (I)
Baseline 3.46 (0.97) 3.35 (1.02) NS
Week 12 3.53 (0.99) 3.37 (1.01) 0.02
BUD- budesonide; FEV1 forced expiratory volume in s; FP fluticasone propionate; FVC- forced vital capacity; PEF- peak expiratory
flow.
ments were seen over the course of the trial in
both patient groups; this decrease, was most
marked during the first 4 weeks of treatment
(Table 5).
There were no significant differences in the
total number of patients reporting exacerba-
tions of asthma (as defined in the protocol)
between the two groups. In all, 41 (16.0%)
patients on FP and 51 (19.5%) of those who
received BUD experienced exacerbations of
asthma during the course of the trial.
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Safety
Adverse events occurred with a similar fre-
quency in both patient groups, with 158
(61.7%) patients treated with FP and 161
(61.5%) of those who received BUD reporting
an adverse event during the course of the trial.
Seven (2.7%) patients in the FP group and 9
(3.4%) on BUD reported adverse events as
serious. However, in only one patient in the
BUD group were these considered to be possi-Comparison offluticasonepropionate with budesonide
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FIG. 2. Evening peak expiratory flow recorded from patient diary record cards.
Table 4. Day- and night-time symptom severity from the patient diary cards
Percentage of days with symptom score < 2
(median)
Percentage of symptom-free nights
(median)
FP BUD p value FP BUD p value
800 lg 600 lg 800 lg 600
Basel ne 33.3 33.3 28.6 33.3
Week 1-4 82.5 81.8 0.17 73.0 73.5 0.18
Week 5-8 89.5 86.4 0.16 77.8 81.5 0.15
Week 9-12 95.2 89.3 0.50 80.0 85.3 0.37
Week 12 85.7 83.3 0.42 73.2 77.5 0.43
The range of minimum and maximum values for percentage of symptom-free nights at baseline was 0-88%. All other ranges were 0-100%.
BUD budesonide; FP fluticasone propionate.
Table 5. Additional bronchodilator use recorded by the patients
Percentage of days with no additional
bronchodilator use (median)
Percentage of nights with no additional
bronchodilator use (median)
FP BUD p value FP BUD p value
800 #g 600 #g 800 Fg 600 #g
Baseline 0.0 0.0 26.7 28.6
Week 1-4 15.1 10.7 0.19 71.4 71.9 0.42
Week 5-8 28.6 13.3 0.06 76.2 76.7 0.22
Week 9-12 35.7 20.0 0.05 80.0 78.8 0.37
Week 1-12 27.8 16.2 0.12 75.9 74.8 0.32
The range of minimum and maximum values for percentage of days with no additional bronchodilator use at baseline was 0-88% in the
fluticasone propionate (FP) group and 0-70% in the budesonide (BUD) group. The range for percentage of nights with no additional
bronchodilator use at baseline was 0-88% in both groups. All other ranges were 0-100%.
bly related to study medication. The most
common adverse events of any severity occur-
ring during therapy are summarized in Table 6.
There were no significant intergroup differ-
ences in frequency.
Mean serum cortisol levels, measured over
the 12-week treatment period, increased by
12.2 nmol/1 from baseline in patients treated
with FP compared with a decrease of
-4.9 nmol/1 from baseline on BUD. In patients
who did not take prednisolone during the trial
(91% of patients on FP; 90% on BUD) the
difference between FP and BUD was more
marked (an increase of 13.5 nmol/1 for FP com-
pared with a decrease of-8.0 nmol/l for BUD).
Analysis of log-transformed values revealed a
statistically significant difference between the
two treatment groups favouring FP (p
0.0002). The adjusted geometric mean ratio was
1.03 for FP and 0.93 for BUD (p 0.0002).
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Table 6. Summary of the most common adverse events on
therapy from case record forms
FP BUD
800g n(%) 1600g n(%)
Patients 256
Patients with adverse events 158 (61.7)
Upper respiratory tract 55 (21.5)
infection
Exacerbation of asthma and 37 (14.5)
related events
Rhinitis/sinusitis 29 (11.3)
Musculoskeletal pain 23 (9.0)
Bronchitis 20 (7.8)
Cerebrovascular 17 (6.6)
Sore throat 15 (5.9)
262
161 (61.5)
65 (24.9)
46 (17.6)
21 (8.0)
13 (5.0)
16(6.1)
15(5.7)
11 (4.2)
Most common is defined as experienced by >4% of patients in
each treatment group. Some patients reported more than one
adverse event. BUD budesonide; FP fluticasone propionate.
There was, however, a statistically significant
interaction between the baseline serum cortisol
values and treatments (p =0.0004). Suppres-
sion of the HPA axis of clinical concern was
seen in six patients (2.3%) on FP compared
with eleven (4.2%) of those who received BUD.
However, this difference did not attain statistical
significance.
Discussion
FP 800#g daily was found to be more
effective than BUD 1 600 bg daily for the treat-
ment of moderate-to-severe asthma in adults,
with the primary efficacy variable of morning
PEF showing a statistically significant advantage
for FP over BUD. During the 12 weeks of
treatment, morning PEF increased by 20.9 1/min
in patients treated with FP compared with only
12.4 1/min on BUD. For purposes of compari-
son, an improvement of 20.0 1/min on therapy
is gene.rally considered to be of clinical signifi-
cance.
6 Analysis of evening PEF, diurnal varia-
tion and percentage predicted PEE as well as
FEV1, FVC and PEF measured at the clinic,
confirms these findings, with statistically signifi-
cant differences in favour of FP for all para-
meters.
International asthma treatment guidelines re-
commending inhaled corticosteroids as first-line
therapy are likely to lead to an increased use of
these agents in asthma.1’2 A stepwise approach,
which increases the dose with increasing sever-
ity of symptoms is recommended, meaning that
some patients with moderate asthma may re-
ceive inhaled corticosteroids at higher dosages
than are currently given as maintenance. Once
symptoms resolve and lung function improves,
the dose is then typically reduced to the mini-
mum required to maintain control. In practice,
however, many physicians initiate therapy at a
high dose, which is then reduced once symp-
toms have been adequately controlled to estab-
lish the optimum maintenance dose.
Inhaled corticosteroids such as BDP and BUD
are generally well tolerated at maintenance
doses. However, studies have shown that high
doses of these agents are associated with an
increased risk of systemic adverse effects, possi-
bly including suppression of the HPA axis,
osteoporosis and growth retardation.4-6 Such
findings clearly indicate the need for inhaled
corticosteroids which combine high topical
potency with higher safety margins for systemic
adverse effects for the treatment of sympto-
matic patients who are currently taking high
doses of these drugs. The results of this study
indicate that FP, as predicted by its potent in
vitro profile, may offer this advantage.
The improvements in lung function seen
during treatment with FP in this trial are
consistent with the results of previous studies
which have shown FP to be at least as effective
as BUD or BDP, even when administered at half
the dosage.
12-17 FP therefore appears to be at
least twice as potent as these older inhaled
corticosteroids in vivo, confirming in vitro
data7
-11
Secondary efficacy variables of day- and night-
time symptom score, additional bronchodilator
use and exacerbations of asthma showed similar
improvements in both treatment groups. Again,
these results are consistent with those of
previous studies.12-17 Both patient groups ex-
perienced an improvement in their asthma
symptoms and required less additional broncho-
dilator therapy. Night-time symptom severity
and bronchodilator use were particularly im-
proved. This is of clinical significance as both
are possible factors which have a major effect
on patient quality-of-life, although this was not
formally studied in this trial.
The overall incidence and type of adverse
events reported on therapy were found to be
comparable in both treatment groups and only
a minority of those adverse events reported
were actually considered to be related to
therapy in any way.
The potential for the two treatments to cause
systemic effects was evaluated by measurement
of serum cortisol levels. FP produced an in-
crease in mean morning serum cortisol levels,
whilst treatment with BUD decreased serum
cortisol levels. The clinical importance of this is
uncertain. Clinically relevant suppression of the
HPA axis was seen in only 2.3% of patients
treated with FP compared with 4.2% of those
who received BUD during this trial.
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In summary, the results of this study show
that FP 800 pg daily is more effective than BUD
1 600 g daily for the treatment of adults with
moderate-to-severe asthma. Superior improve-
ments were seen in PEF with FP, even at half
the dose of BUD. In contrast to BUD, FP at this
relatively high dose had less effect on HPA axis
function as measured by serum cortisol levels,
indicating a superior efficacy:safety ratio. These
findings support the use of FP in adult patients
who require inhaled corticosteroids to further
improve their asthma control.
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